Correlation Study of Annexin A2 and Prognosis of Glioblastoma

马凯明,陈素华,陈新,刘维海,赵晓芳,杨辰龙,杨军
DOI: https://doi.org/10.3969/j.issn.1009-6604.2023.03.005
2023-01-01
Abstract:Objective To investigate the correlation between annexin A2(ANXA2) and the prognosis of glioblastoma(GBM). Methods This case-control study was conducted on 103 glioblastoma patients with complete clinical data included in the Cancer Genome Atlas(TCGA). The independent variables included ANXA2 transcription level and other clinical factors, and the dependent variable was the overall survival(OS) time of patients. According to the OS, the patients were divided into case group(OS<8 months) and control group(OS ≥ 8 months). Restricted cubic spline(RCS) analysis, univariate and multivariate logistic regression analysis were used to explore the effect of ANXA2 in GBM tumor tissue on the prognosis of patients. Results Univariate analysis showed that the mRNA expression of ANXA2(OR=4.992,P=0.000), age(OR=9.320,P=0.000), O~6-methylguanine-DNA methyltransferase(MGMT) promoter methylation(OR=3.875,P=0.001) and TCGA mesenchymal subtype(OR=4.168,P=0.001) were associated with poor prognosis in GBM patients. Further RCS analysis showed that the risk of poor prognosis in GBM patients increased with the rise of ANXA2 transcription level. The results of multivariate logistic regression analysis showed that there was an independent dose-response relationship between ANXA2 transcription level and poor prognosis under the combined effect of age, MGMT promoter methylated type and TCGA mesenchymal type(OR=38.684, P=0.000). Conclusion There is an independent dose-response relationship between ANXA2 transcription in GBM tumor tissues and the risk of poor prognosis, which illustrates that ANXA2 is an independent prognostic factor for GBM patients.
What problem does this paper attempt to address?